Evofem Biosciences Shares Outstanding 2013-2022 | EVFM

Evofem Biosciences shares outstanding from 2013 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Evofem Biosciences Annual Shares Outstanding
(Millions of Shares)
2021 9
2020 4
2019 3
2018 1
2017 0
2016 0
2015 0
2014 0
2013 0
2012 0
Evofem Biosciences Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30 27
2022-03-31 11
2021-12-31 9
2021-09-30 10
2021-06-30 8
2021-03-31 5
2020-12-31 4
2020-09-30 5
2020-06-30 4
2020-03-31 3
2019-12-31 3
2019-09-30 3
2019-06-30 2
2019-03-31 2
2018-12-31 1
2018-09-30 2
2018-06-30 1
2018-03-31 1
2017-12-31 0
2017-09-30 0
2017-06-30 0
2017-03-31 0
2016-12-31 0
2016-09-30 0
2016-06-30 0
2016-03-31 0
2015-12-31 0
2015-09-30 0
2015-06-30 0
2015-03-31 0
2014-12-31 0
2014-09-30 0
2014-06-30 0
2014-03-31 0
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.005B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.286B 9.60
GSK (GSK) United Kingdom $71.707B 8.61
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.077B 18.55
Biohaven Pharmaceutical Holding (BHVN) United States $10.582B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.645B 0.00
Arcus Biosciences (RCUS) United States $1.982B 38.68
Myovant Sciences (MYOV) United Kingdom $1.693B 0.00
Emergent Biosolutions (EBS) United States $1.465B 8.49
Zymeworks (ZYME) Canada $0.405B 0.00
Enzo Biochem (ENZ) United States $0.132B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
Ambrx Biopharma (AMAM) United States $0.099B 0.00
SQZ Biotechnologies (SQZ) United States $0.096B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00